Backing UK Biotech
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Jefferies 2013 Global Healthcare Conference in London
Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc. -
Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT -
March 2018 1 MARKET UPDATE| HEALTHCARE
MARKET UPDATE| HEALTHCARE MARKET UPDATE HEALTHCARE March 2018 1 MARKET UPDATE| HEALTHCARE HIGHLIGHTS Dear Reader, 2017 ended with the $69 billion CVS Health / Aetna deal. Pharmacy +6.5% Benefit Manager (PBM) consolidation took another major step this month 5Y-CAGR with Cigna scooping up the largest independent PBM, Express Scripts, in a $52 billion deal. Additionally, rumor has it that Walmart is in the early Worldwide stages talks with insurer Humana, looking at a variety of options including prescription drugs - an acquisition. The frenzy might very well be due to Amazon’s debut in expected sales healthcare and the looming shadow of its entrance in the pharmacy market. But Amazon is also putting pressure on consumer care products, intensifying price competition. In response, pharmaceuticals groups are +5.3% parted between those which want to hold on to these products that are 5Y-CAGR generally durable brands with loyal customers, and others which doubt Medtech market - their long-term stable returns. GlaxoSmithKline had us hold our breath: expected growth after entering - and eventually quitting - the race to buy Pfizer’s consumer healthcare business for a price tag hoped to be as much as $20 billion, the company bought Novartis out of their consumer healthcare joint venture for $13 billion. GSK is thus taking full control of products -0.7%/-2.2% including Sensodyne toothpaste, Panadol headache tablets and muscle gel Monthly EU Pharma & Voltaren. biotech performance March was also home to remarkable market transactions in the biotech and medtech fields that had us quite excited, beyond the fact that Bryan, Garnier & Co. -
RCP BIA 2020 Review January 2021 FINAL.Pdf
UK BioIndustry Association UK Listed Biotech & Life Sciences 2020 – Year in Review– May you live in interesting times Radnor Broad UK Listed Biotech Index - 2 Year Chart Unweighted Weighted FTSE All-Share 350 300 250 200 150 100 50 Dec '20 Dec Dec '18 Dec '19 Mar '19 Jun '19 Sep '19 Dec '20 Mar '20 Jun '20 Sep Source: FactSet, Radnor 2020 has been an extraordinary year across the market but there is no doubt that the UK listed biotech sector has been in the front line in more ways than one. Investors have clearly responded to both the efforts made by the sector to combat the pandemic, but also the structural growth opportunity within biotech that the pandemic has bought into sharper focus. Not only have we seen headline share price underperformance reverse sharply through the course of 2020, but critically, the pace and scale of sector fundraising activity has stepped up materially. Perhaps most importantly, the number of investors active in the sector (institutional, private wealth, individual and overseas) have expanded. This feature alone has gone a long way towards addressing one of the key issues facing the sector. The BioIndustry Association ▪ Sector Outperformance. 2020 has been the strongest period of price is a research client of Radnor outperformance over the last 10 years. Interestingly, this outperformance has Capital Partners Ltd. been delivered across all the sub-indices making up the Broad Biotech index; although performance levels have varied somewhat. This outperformance has MiFID II – this research is also been much more pronounced then looking at the sector on an equal deemed to be a minor, non- monetary benefit. -
Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP
Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767% -
Oxford Biomedica Delivering Commercial Gene-Therapy Vector
31st March 2017 Pharmaceuticals & Biotechnology Oxford BioMedica Delivering commercial gene-therapy vector OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties Source: Fidessa on commercial products developed with its LentiVector® platform: extensive IP, facilities, and know-how for production and development of lentiviral vectors to Market data generate gene-based therapies. OXB intends to out-license its five clinical EPIC/TKR OXB candidates and to continue investment in R&D. Bioprocessing royalties are likely Price (p) 5.2 to result in significant upside potential in the near future. 12m High (p) 6.5 12m Low (p) 3.0 ► Strategy: Oxford BioMedica has four strategic objectives: delivery of process Shares (m) 3,088.2 development services which embed its technology in partners’ commercial Mkt Cap (£m) 159.0 products; commercial manufacture of lentiviral vector; out-licensing of EV (£m) 178.1 proprietary candidates; and investment in R&D and the LentiVector platform. Free Float 65% Market LSE ► Revenues: Bioprocessing and process development command fees-for-service, with process development also incurring upfront, milestone and incentive Description payments plus licensing income and royalties on commercial products. Out- Oxford BioMedica is a UK-based licensed candidates will deliver licensing fees plus high royalties if successful. biopharmaceutical company specializing in cell and gene therapies developed using lentiviral vectors, ► Valuation: An EV/sales multiple of 4x prospective sales for the bioprocessing gene-delivery vehicles based on virus and process development services is readily justified, which generates a value particles. -
Guidelines with Regard to the Composition, Calculation and Management of the Index
INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index. -
List of Section 13F Securities, First Quarter, 2014
List of Section 13F Securities First Quarter FY 2014 Copyright (c) 2014 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2014, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2014. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by [ Section 13(f)(1) and Rule 13f-1] thereunder. -
Misinterpretation of Time-To-First Event Curves Can Lead to Inappropriate Treatment
AGORA | CORRESPONDENCE Misinterpretation of time-to-first event curves can lead to inappropriate treatment To the Editor: Great care should be taken when assessing the consistency of treatment effect over time based on a survival curve plot, and even more so when a treatment affects a repeating event end-point, such as exacerbations, rather than an event that can occur only once, like death. In their recent editorial in the European Respiratory Journal,SUISSA and ARIEL [1] make the assertation that survival functions plotted from Kaplan–Meier estimates from figure 1b in the IMPACT study [2] “clearly show that the difference in the rate of exacerbation between LAMA/LABA/ICS and LAMA/LABA over follow-up is due to the first month’s surge, with practically no differences in the subsequent rates between the two groups”. However, this statement is based on a misunderstanding of the survival analyses presented. The events plotted on the figure are the first moderate or severe COPD exacerbations experienced by a patient in the IMPACT study. The statements made by SUISSA and ARIEL [1] about exacerbation rates refer to the rate of first exacerbations only, and not to the rate of all exacerbations during the study. Their conclusion that the rates of first exacerbations, and ratio between those rates changes over time is correct. However, this is entirely in line with statistical theory for repeated events with overall constant rates. It cannot be used to support any conclusion that the difference in the rate of exacerbation is due to a “first month’s surge”. The “digitised” curve of first events behaves entirely consistently with constant rate events. -
FTSE Russell Publications
2 FTSE Russell Publications 19 August 2021 FTSE 250 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Infrastructure 0.43 UNITED Bytes Technology Group 0.23 UNITED Edinburgh Investment Trust 0.25 UNITED KINGDOM KINGDOM KINGDOM 4imprint Group 0.18 UNITED C&C Group 0.23 UNITED Edinburgh Worldwide Inv Tst 0.35 UNITED KINGDOM KINGDOM KINGDOM 888 Holdings 0.25 UNITED Cairn Energy 0.17 UNITED Electrocomponents 1.18 UNITED KINGDOM KINGDOM KINGDOM Aberforth Smaller Companies Tst 0.33 UNITED Caledonia Investments 0.25 UNITED Elementis 0.21 UNITED KINGDOM KINGDOM KINGDOM Aggreko 0.51 UNITED Capita 0.15 UNITED Energean 0.21 UNITED KINGDOM KINGDOM KINGDOM Airtel Africa 0.19 UNITED Capital & Counties Properties 0.29 UNITED Essentra 0.23 UNITED KINGDOM KINGDOM KINGDOM AJ Bell 0.31 UNITED Carnival 0.54 UNITED Euromoney Institutional Investor 0.26 UNITED KINGDOM KINGDOM KINGDOM Alliance Trust 0.77 UNITED Centamin 0.27 UNITED European Opportunities Trust 0.19 UNITED KINGDOM KINGDOM KINGDOM Allianz Technology Trust 0.31 UNITED Centrica 0.74 UNITED F&C Investment Trust 1.1 UNITED KINGDOM KINGDOM KINGDOM AO World 0.18 UNITED Chemring Group 0.2 UNITED FDM Group Holdings 0.21 UNITED KINGDOM KINGDOM KINGDOM Apax Global Alpha 0.17 UNITED Chrysalis Investments 0.33 UNITED Ferrexpo 0.3 UNITED KINGDOM KINGDOM KINGDOM Ascential 0.4 UNITED Cineworld Group 0.19 UNITED Fidelity China Special Situations 0.35 UNITED KINGDOM KINGDOM KINGDOM Ashmore -
Saving UK Biotech
January 22, 2009 Saving UK Biotech Evaluate Vantage While news of the death of the UK biotechnology industry maybe exaggerated, despite a recent spate of companies falling into administration and big pharma picking off some of the best and brightest hopes in the sector, a report into the state of the industry by the Bioscience Innovation and Growth Team published today indicated that an ambulance might be called for unless drastic measures are taken. Chief among the calls from the group, which is supported by the UK’s industry champion, the Biotech Industry Association, was the need for more tax incentives, especially for the pharmaceutical industry to make investments in smaller biotechnology businesses more attractive, in order to ensure the health of the sector. Speedier approvals The National Institute for Health and Clinical Excellence (NICE), which decides on which drugs will be used in the UK’s health service was also identified as a potential barrier to drug innovation, due to the length of time it takes to decide on whether to use drugs. Sir David Cooksey, who was presenting the review on progress made in the industry since 2003, said that the average time between approval of a drug and its introduction by NICE often equated to a third of the patent life of the drug, leaving innovator companies less time to recoup the cost of drug discovery and potentially driving prices up. But the most controversial proposal today was the suggestion that drugs in phase II be used commercially in the UK, whilst waiting for approval, allowing orginators to recoup the cost of development at an earlier stage. -
International Smallcap Separate Account As of July 31, 2017
International SmallCap Separate Account As of July 31, 2017 SCHEDULE OF INVESTMENTS MARKET % OF SECURITY SHARES VALUE ASSETS AUSTRALIA INVESTA OFFICE FUND 2,473,742 $ 8,969,266 0.47% DOWNER EDI LTD 1,537,965 $ 7,812,219 0.41% ALUMINA LTD 4,980,762 $ 7,549,549 0.39% BLUESCOPE STEEL LTD 677,708 $ 7,124,620 0.37% SEVEN GROUP HOLDINGS LTD 681,258 $ 6,506,423 0.34% NORTHERN STAR RESOURCES LTD 995,867 $ 3,520,779 0.18% DOWNER EDI LTD 119,088 $ 604,917 0.03% TABCORP HOLDINGS LTD 162,980 $ 543,462 0.03% CENTAMIN EGYPT LTD 240,680 $ 527,481 0.03% ORORA LTD 234,345 $ 516,380 0.03% ANSELL LTD 28,800 $ 504,978 0.03% ILUKA RESOURCES LTD 67,000 $ 482,693 0.03% NIB HOLDINGS LTD 99,941 $ 458,176 0.02% JB HI-FI LTD 21,914 $ 454,940 0.02% SPARK INFRASTRUCTURE GROUP 214,049 $ 427,642 0.02% SIMS METAL MANAGEMENT LTD 33,123 $ 410,590 0.02% DULUXGROUP LTD 77,229 $ 406,376 0.02% PRIMARY HEALTH CARE LTD 148,843 $ 402,474 0.02% METCASH LTD 191,136 $ 399,917 0.02% IOOF HOLDINGS LTD 48,732 $ 390,666 0.02% OZ MINERALS LTD 57,242 $ 381,763 0.02% WORLEYPARSON LTD 39,819 $ 375,028 0.02% LINK ADMINISTRATION HOLDINGS 60,870 $ 374,480 0.02% CARSALES.COM AU LTD 37,481 $ 369,611 0.02% ADELAIDE BRIGHTON LTD 80,460 $ 361,322 0.02% IRESS LIMITED 33,454 $ 344,683 0.02% QUBE HOLDINGS LTD 152,619 $ 323,777 0.02% GRAINCORP LTD 45,577 $ 317,565 0.02% Not FDIC or NCUA Insured PQ 1041 May Lose Value, Not a Deposit, No Bank or Credit Union Guarantee 07-17 Not Insured by any Federal Government Agency Informational data only.